Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA.
The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds.
Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.
The title of Aprea’s poster presentation at AACR was “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients”.
In the studies, the anticancer effect of APR-246 alone, and in combination with platinum compounds, on ovarian cancer cells were investigated.
The results show that APR-246 acts synergistically with platinum compounds and reverses the cisplatin-sensitivity to cisplatin-resistant p53 mutant ovarian cancer cells.
Aberrations in p53 are common in many cancer forms and are associated with increased resistance to standard chemotherapy resulting in a poor prognosis for the patient. About 60% of ovarian cancer patients have p53 mutations.
Mikael von Euler, CMO of Aprea, commented; “We are very pleased with this comprehensive set of preclinical data supporting our planned Phase II study in platinum-resistant Epithelial Ovarian Cancer (EOC) patients who are candidates for further platinum-based chemotherapy. APR-246 has the potential to be an important new treatment for these patients with high unmet medical need”.